Theravance begins a new chapter on 15 May when it splits into two companies known as Theravance Royalty Management and Theravance Biopharma – the former charged with collecting cash from the sale of respiratory medicines partnered with GlaxoSmithKline and the latter focused on research and development.
CEO Rick Winningham is looking forward to the end of Theravance's separation process, which the South San Francisco-based company kicked...